Drugs that contain Ibrutinib
1. Drug name - IMBRUVICA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8697711 | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8957079 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US9181257 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US7514444 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8735403 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8008309 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(5 years from now) | |
| US9725455 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10125140 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10106548 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9296753 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(11 years from now) | |
| CN103319488A | PHARMACYCLICS INC | A Bruton ' S Tyrosine Kinase Inhibitor |
Nov, 2016
(5 years ago) | |
| CN104736178A | PHARMACYCLICS INC | Crystalline Form Of Bruton Tyrosine Kinase Inhibitor |
Jan, 2020
(2 years ago) | |
| CN102887900B | PHARMACYCLICS INC | Inhibitor Of Bruton ' S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN102887900A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN102746305B | PHARMACYCLICS INC | Inhibitor Of Bruton ' S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN101805341A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN101610676B | PHARMACYCLICS INC | Inhibitor Of Bruton Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN101805341B | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN101610676A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN102746305A | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| CN101674834A | PHARMACYCLICS INC | A Bruton ' S Tyrosine Kinase (Bruton ' S Tyrosine Kinase Inhibitor |
Mar, 2028
(5 years from now) | |
| CN101674834B | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| IN201205631P1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| IN362133B | PHARMACYCLICS INC | Inhibitors Of Bruton&Amp;Apos;S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| IN200901642P1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2029
(6 years from now) | |
| EP2529622B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Feb, 2019
(3 years ago) | |
| EP2529622A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Feb, 2019
(3 years ago) | |
| EP2201840B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Jul, 2020
(2 years ago) | |
| EP2201840A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Jul, 2020
(2 years ago) | |
| EP2526933A3 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2081435B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2081435A4 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2526771A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2526933B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2530083A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2081435A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2530083B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2526771B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2526933A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2526934A3 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2526934A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2529621B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2529621A1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2526934B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Dec, 2026
(4 years from now) | |
| EP2139487A2 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| EP2139487B1 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| EP2139487A4 | PHARMACYCLICS INC | Inhibitors Of Bruton'S Tyrosine Kinase |
Mar, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754091 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8476284 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8703780 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8952015 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8497277 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(4 years from now) | |
| US8563563 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(4 years from now) | |
| US10478439 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801883 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9125889 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801881 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US8754090 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US8999999 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10004746 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10016435 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9814721 | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US10751342 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10653696 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US10752634 | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10961251 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294232 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9713617 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294231 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9540382 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(10 years from now) | |
| US9795604 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(12 years from now) | |
| US10463668 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(12 years from now) | |
| US10695350 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(12 years from now) | |
| US9655857 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10010507 | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10213386 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
| US10828259 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
Treatment: Treatment of waldenstrom's macroglobulinemia; treatment of mantle cell lymphoma; treatment of marginal zone lymphoma; treatment of small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia; treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; treatment of mantle cell lymphoma; treatment of marginal zone lymphoma; treatment of chronic lymphocytic leukemia; treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of mantle cell lymphoma; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of marginal zone lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; Treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma; treatment of chronic graft versus host disease after failure of one or more lines of systemic therapy; treatment of mantle cell lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; treatment of marginal zone lymphoma; treatment of chronic lymphocytic leukemia; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma; For the treatment of patients with waldenstrom's macroglobulinemia; treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia; Treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia; treatment of small lymphocytic leukemia; treatment of chronic lymphocytic leukemia; treatment for chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; Treatment of waldenstrom's macroglobulinemia; Treatment of marginal zone lymphoma; Treatment of relapsed or refractory small lymphocytic lymphoma; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of relapsed or refractory chronic lymphocytic leukemia; Treatment of marginal zone lymphoma; treatment of mantle cell lymphoma; treatment of chronic lymphocytic leukemia; treatment of small lymphocytic lymphoma; treatment of waldenstrom's macroglobulinemia; treatment of chronic lymphocytic leukemia; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; treatment of adult patients with cyclosporin-resistant, steroid-dependent/refractory, or steroid resistant chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; Treatment of refractory chronic graft-versus-host disease; Treatment of chronic graft versus host disease refractory to systemic therapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 140MG | TABLET;ORAL | Prescription |
| 280MG | TABLET;ORAL | Prescription |
| 420MG | TABLET;ORAL | Prescription |
| 560MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.